Informed Prostate Cancer Patient Support

Reproducibility of PSMA PET/CT Imaging for primary staging of treatment-naïve prostate cancer patients depends on the applied radiotracer: a retrospective study | Journal of Nuclear Medicine

Risk of progression following a negative biopsy in prostate cancer active surveillance | Prostate Cancer and Prostatic Diseases nature.com Risk of progression following a negative biopsy in prostate cancer active surveillance Elhage, Oussama 34-43 minutes Abstract Background Currently, follow-up protocols are applied equally to men on active surveillance (AS) for prostate cancer (PCa) regardless of findings at their initial follow-up biopsy. To determine whether less intensive follow-up is suitable following negative biopsy findings, we assessed the risk of converting to active treatment, any subsequent upgrading, volume progression (>33% positive cores), and serious upgrading (grade group >2) for negative compared with positive findings on initial follow-up biopsy. Methods 13,161 men from 24 centres participating in the Global Action Plan Active Surveillance Prostate Cancer [GAP3] c

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 - ScienceDirect

Diagnostics | Free Full-Text | Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation

Extended Results and Independent Validation of a Phase 2 Trial of Metastasis Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer - International Journal of Radiation Oncology, Biology, Physics redjournal.org Extended Results and Independent Validation of a Phase 2 Trial of Metastasis Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer Purpose The role of metastasis-directed therapy (MDT) in molecularly defined oligorecurrent prostate cancer (PCa) remains irresolute. We present extended follow-up and an independent validation cohort of a prospective trial. Methods and Materials This study consists of 2 sequential single-arm phase-2 trials of patients with biochemical recurrence (prostate specific antigen [PSA] 0.4-3.0 ng/mL) and negative conventional imaging after radical prostatectomy and postoperative radiation therapy. All patients underw

Prostate Cancer Treatment Resistant healthline.com How Prostate Cancer Becomes Resistant to Treatment George Citroner 6-7 minutes Researchers say they may have unlocked the mystery of resistant prostate cancer. They hope it’ll lead to better treatments. Share on Pinterest Researchers say a molecular “switch” can lead to prostate cancers becoming treatment-resistant. Getty Images It’s the second most diagnosed cancer in men, just behind skin cancer. It’s typically slow growing and there are life-saving treatments available. But, sometimes the cure can make prostate cancer Trusted Source more deadly. A new study released today from Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California, details how prostate cancer can be transformed into an aggressive and incurable disease — by the treatment that’s supposed to save lives. Hormones called androgens stimulate prostate canc

STAT3 restricts prostate cancer metastasis and antiandrogen resistance by controlling LKB1/CREB signaling pathway | bioRxiv

Metformin, Testosterone Replacement Linked to Reduced Cancer Risk

Risk of progression following a negative biopsy in prostate cancer active surveillance | Prostate Cancer and Prostatic Diseases

piv-prognostic-role-in-mcrpc-treated-patients-with-arsis

Immunotherapy drug combination stimulates immune system against resistant cancers - The Institute of Cancer Research, London

Study finds betamethasone may enhance effectiveness of radiation therapy for prostate cancer – ThePrint – ANIFeed

Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer | British Journal of Cancer

Frozen section utilization to omit systematic biopsy in diagnosing high risk prostate cancer | Scientific Reports

2D Genetic Map of Prostate Cells Charts Cancer Growth | The Scientist Magazine® the-scientist.com 2D Genetic Map of Prostate Cells Charts Cancer Growth 6-8 minutes I n a study published August 10 in Nature , scientists have charted the genetic landscape across a human prostate in high resolution and discovered how additional or missing chunks of chromosomes, known as copy number variations, thought to be unique to cancer are often present in seemingly healthy tissue. “This was surprisingly and completely unexpected,” says study coauthor Alastair Lamb , a urologist at Oxford University’s Nuffield Department of Surgical Sciences. “We thought that these kinds of changes defined prostate cancer. But they are present in [tissue] which is entirely benign.” Far from a uniform mass of cells, tumors consist of a patchwork of malignant, benign, and healthy tissues. Understanding how normal cells

Long-term benefit of radiotherapy confirmed in advanced prostate cancer

What will study reveal about prostate cancer? | News, Sports, Jobs - The Mining Journal

Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience | PLOS ONE

Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer | British Journal of Cancer

EU OKs novel biomarker and machine learning–powered test for prostate cancer urologytimes.com EU OKs novel biomarker and machine learning–powered test for prostate cancer Jason M. Broderick 3-4 minutes European CE Marketing for In Vitro Diagnostic medical devices (CE-IVD Mark) has been granted to the ClarityDX Prostate test, a biomarker and machine learning–powered test for clinically significant prostate cancer, according to Nanostics Inc., the developer of the test. 1 Using a machine-learning algorithm, ClarityDX Prostate assesses a combination of clinical and biological biomarker data and provides a risk score for a patient’s biopsy showing a clinically significant prostate cancer (Gleason grade group ≥2). According to Nanostics, the purpose of ClarityDX Prostate is to serve as a reflex test for helping patients with elevated PSA levels have more informed conversations with their p

Cost-effectiveness of the implementation of [68Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging | Insights into Imaging | Full Text

Identification and Validation of Three Hub Genes Involved in Cell Proliferation and Prognosis of Castration-Resistant Prostate Cancer

Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis - ScienceDirect

Factors influencing survival in metastatic castration resistant prostate cancer therapy: Expert Review of Anticancer Therapy: Vol 0, No ja

Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3–5) and Negative Initial Biopsy. A Mini Systematic Review - ScienceDirect

Long-term benefit of radiotherapy confirmed in advanced prostate cancer - The Institute of Cancer Research, London

Association between cannabis use with urological cancers: A population‐based cohort study and a mendelian randomization study in the UK biobank

Application of European‐specific polygenic risk scores for predicting prostate cancer risk in different ancestry populations - Ruan - The Prostate - Wiley Online Library

Quality-of-Life Outcomes and Toxicity Profile Among Patients with Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multi-Center Phase 2 Trial - ScienceDirect

S-nitrosoglutathione Inhibits the Growth of Androgen-Receptor Dependent and Castration Resistant Prostate Cancer by Modulating FOXM1 Signaling | bioRxiv

New cancer treatment offers hope to patients out of options | Cancer research | The Guardian theguardian.com New cancer treatment offers hope to patients out of options Andrew Gregory 5-7 minutes A new cancer treatment can stop the disease advancing in patients who are resistant to immunotherapy, doctors have discovered. Immunotherapy uses the immune system to target and kill cancer cells, and can save lives when other treatment options, such as surgery, radiotherapy or chemotherapy, have failed. However, it cannot help all patients, and some tumours can evolve to resist it. Now oncologists in the UK have found a two-pronged treatment – immunotherapy combined with guadecitabine, a novel experimental drug – can reverse a cancer’s resistance to immunotherapy. Patients expected to die after exhausting all treatment options survived much longer, they found. The combination of pembrolizumab,

Quality-of-Life Outcomes and Toxicity Profile Among Patients with Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multi-Center Phase 2 Trial - International Journal of Radiation Oncology, Biology, Physics

Deciphering the enigmatic crosstalk between prostate cancer and Alzheimer's disease: A current update on molecular mechanisms and combination therapy - ScienceDirect

Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer | Radiology

Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future | Nature Reviews Urology

Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling | Science

10 Warning Signs Of Cancer You MUST Know About - YouTube

How You Feel About Aging Could Affect Health. Here’s How to Keep the Right Attitude | Cooking with Kathy Man

Considering genetic risk in prostate cancer referrals could lead to earlier diagnosis -- ScienceDaily

Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy - Filon - The Prostate - Wiley Online Library

Androgen receptor condensates as drug targets | bioRxiv

Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer | Clinical Cancer Research | American Association for Cancer Research

Circulating microRNA profiling for prediction of oncological outcomes in prostate cancer patients following radical prostatectomy - Takamori - The Prostate - Wiley Online Library

New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index - Terracciano - The Prostate - Wiley Online Library

FDA approves darolutamide tablets for metastatic hormone-sensitive prostate cancer | FDA fda.gov FDA approves darolutamide tablets for metastatic hormone-sensitive pro 4-5 minutes On August 5, 2022, the Food and Drug Administration approved darolutamide (Nubeqa, Bayer HealthCare Pharmaceuticals Inc.) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC). Efficacy was based on ARASENS (NCT02799602), a randomized, multicenter, double-blind, placebo-controlled clinical trial in 1306 patients with mHSPC. Patients were randomized to receive either darolutamide 600 mg orally twice daily plus docetaxel 75 mg/m 2 intravenously administered every 3 weeks for up to 6 cyc

Genetic mapping of tumors reveals how cancers grow -- ScienceDaily sciencedaily.com Genetic mapping of tumors reveals how cancers grow 3-4 minutes Understanding which cells give rise to which areas of cancer can improve our understanding of how a tumour has grown and developed, including how it has changed genetically, over time. This has been made possible using a new technique called spatial transcriptomics, which allows scientists to see what genetic changes take place without breaking up the tissue they're looking at. This adds a new dimension which researchers have now used to reveal which cells have mutated and where within the ecosystem of an organ. Current techniques for studying the genetics of cells within tumours involve taking a sample from the cancerous area and analysing the DNA of those cells. The problem is that many cancers, such as prostate cancer, are three dim

How brain surgeon Henry Marsh went from doctor to patient: ‘I blurted out the question we all ask – how long have I got?’ | Health | The Guardian :  theguardian.com How brain surgeon Henry Marsh went from doctor to patient: ‘I blurted out the question we all ask – how long have I got?’ Henry Marsh 23-28 minutes I t seemed a bit of a joke at the time – that I should have my own brain scanned. I should have known better. I had always advised patients and friends to avoid having brain scans unless they had significant problems. You might not like what you see, I told them. I had volunteered to take part in a study of brain scans in healthy people. I was curious to see my own brain, if only in the greyscale pixels of an MRI scan. I had spent much of my life looking at brain scans or living brains when operating, but the awe I felt as a medical student when seeing brain surgery for the first

The application of patient reported outcomes (PROs) to build personalized patient education aids - International Journal of Radiation Oncology, Biology, Physics

PIRADS for Rad Oncs: A Multidisciplinary Educational Lecture to Improve Prostate MRI Interpretation for Radiation Oncology Residents - ScienceDirect

Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer | Scientific Reports

PSA Nadir Level in Prostate Cancer

PSA provocation by bipolar androgen therapy may predict duration of response to first‐line androgen deprivation: Updated results from the BATMAN study - Denmeade - The Prostate - Wiley Online Library

Circulating tumor DNA profiling approach based on in silico background elimination guides patient classification of multiple cancers | bioRxiv

CV Admissions on the Rise in Americans With Cancer

Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies | Prostate Cancer and Prostatic Diseases

Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies | Prostate Cancer and Prostatic Diseases

Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer | Clinical Cancer Research | American Association for Cancer Research

How different cancer cells respond to drug-delivering nanoparticles: The findings of a large-scale screen could help researchers design nanoparticles that target specific types of cancer -- ScienceDaily

Prostate cancer grade downgrading at time of prostatectomy provides risk‐stratification insight into future tumor behavior after prostatectomy - Wang - The Prostate - Wiley Online Library

Prostate cancer cases risk being detected too late due to misleading focus on urinary problems -- ScienceDaily sciencedaily.com Prostate cancer cases risk being detected too late due to misleading focus on urinary problems 5-6 minutes Men with early, curable stages of prostate cancer are missing opportunities to have their cancer detected because national guidelines and media health campaigns focus on urinary symptoms despite a lack of scientific evidence, say experts at the University of Cambridge. Prostate cancer is the most common type of cancer in men. According to Cancer Research UK, over 52,000 men are diagnosed with prostate cancer each year and there are more than 12,000 deaths. Over three-quarters (78%) of men diagnosed with the disease survive for over ten years, but this proportion has barely changed over the past decade in the UK, largely because the disease is detected at

Cureus | Metastatic Prostate Adenocarcinoma Presenting as Acute Quadriplegia: A Case Report and Racial Disparity Analysis

The Risk of Second Primary Cancer After Prostate Radiotherapy medscape.com The Risk of Second Primary Cancer After Prostate Radiotherapy Megan Brooks 4-5 minutes Men with localized prostate cancer that is treated with radiotherapy have a small but statistically elevated risk for a second primary cancer compared with peers who do not undergo radiotherapy, a large retrospective study has found. The rate of developing a second primary cancer was 3.7% in the radiotherapy cohort, vs 2.5% in the nonradiotherapy cohort. This difference is "quite low" and "should not deter physicians from encouraging their patients to pursue radiotherapy as a curative treatment for prostate cancer," lead author Hilary Bagshaw, MD, Department of Radiation Oncology, Stanford University and Cancer Institute, Palo Alto, California, told Medscape Medical News . The study was published online Jul